📣 VC round data is live. Check it out!

iNtRON Biotechnology Valuation Multiples

Discover revenue and EBITDA valuation multiples for iNtRON Biotechnology and similar public comparables like HAEMATO, Applied BioCode, Pangaea Oncology, Osang Healthcare and more.

iNtRON Biotechnology Overview

About iNtRON Biotechnology

iNtRON Biotechnology Inc is a Korea-based company principally engaged in the biotechnology industry. It develops, manufactures, and commercializes drugs for the treatment of infectious diseases. It is contributing to national health and national prevention through several (molecular) diagnostic products such as swine flu, VRE super bacteria, food poisoning, avian influenza and foot, and mouth disease. In addition, it is also engaged in the operation of a veterinary antibiotic alternative business and new biopharmaceuticals development business.


Founded

1999

HQ

South Korea

Employees

N/A

Financials (FY)

Revenue: $4M
EBITDA: ($5M)

EV

$45M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

iNtRON Biotechnology Financials

iNtRON Biotechnology reported last fiscal year revenue of $4M and negative EBITDA of ($5M).

In the same fiscal year, iNtRON Biotechnology generated $2M in gross profit, ($5M) in EBITDA losses, and had net loss of ($6M).


iNtRON Biotechnology P&L

In the most recent fiscal year, iNtRON Biotechnology reported revenue of $4M and EBITDA of ($5M).

iNtRON Biotechnology is unprofitable as of last fiscal year, with gross margin of 54%, EBITDA margin of (122%), and net margin of (156%).

See analyst estimates for iNtRON Biotechnology
Last FY202320242025202620272028
Revenue$4M$7M$4M$4M
Gross Profit$2M$4M$3M$2M
Gross Margin54%61%58%54%
EBITDA($5M)($4M)($655K)($5M)
EBITDA Margin(122%)(63%)(15%)(122%)
EBIT Margin(138%)(34%)(82%)(138%)
Net Profit($6M)($7M)($2M)($6M)
Net Margin(156%)(101%)(40%)(156%)

Financial data powered by Morningstar, Inc.

iNtRON Biotechnology Stock Performance

iNtRON Biotechnology has current market cap of $72M, and enterprise value of $45M.


iNtRON Biotechnology's stock price is $2.32.

iNtRON Biotechnology has an EPS (earnings per share) of $-0.20.

See more trading valuation data for iNtRON Biotechnology
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$45M$72M-0.4%$-0.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

iNtRON Biotechnology Valuation Multiples

iNtRON Biotechnology trades at 11.6x EV/Revenue multiple, and (9.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for iNtRON Biotechnology

iNtRON Biotechnology Financial Valuation Multiples

As of May 10, 2026, iNtRON Biotechnology has market cap of $72M and EV of $45M.

iNtRON Biotechnology has a P/E ratio of (11.7x).

Last FY202320242025202620272028
EV/Revenue11.6x6.9x10.3x11.6x
EV/EBITDA(9.5x)(11.0x)(69.3x)(9.5x)
EV/EBIT(8.4x)(20.2x)(12.7x)(8.4x)
EV/Gross Profit21.4x11.3x17.7x21.4x
P/E(11.7x)(10.8x)(40.4x)(11.7x)
EV/FCF(8.6x)(10.3x)(50.0x)(8.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified iNtRON Biotechnology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

iNtRON Biotechnology Margins & Growth Rates

In the most recent fiscal year, iNtRON Biotechnology reported gross margin of 54%, EBITDA margin of (122%), and net margin of (156%).

See estimated margins and future growth rates for iNtRON Biotechnology

iNtRON Biotechnology Margins

Last FY20242025202720282029
Gross Margin54%58%54%
EBITDA Margin(122%)(15%)(122%)
EBIT Margin(138%)(82%)(138%)
Net Margin(156%)(40%)(156%)
FCF Margin(134%)(21%)(134%)

iNtRON Biotechnology Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(33%)(11%)
Gross Profit Growth(36%)(17%)
EBITDA Growth(84%)631%
EBIT Growth59%51%
Net Profit Growth(73%)246%
FCF Growth(79%)480%

Data powered by FactSet, Inc. and Morningstar, Inc.

iNtRON Biotechnology Operational KPIs

Access forward-looking KPIs for iNtRON Biotechnology
Last FY202320242025202620272028
S&M Expenses to Revenue11%11%8%11%
G&A Expenses to Revenue18%13%15%18%
R&D Expenses to Revenue81%33%54%81%
Opex to Revenue192%95%140%192%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

iNtRON Biotechnology Competitors

iNtRON Biotechnology competitors include HAEMATO, Applied BioCode, Pangaea Oncology, Osang Healthcare, electroCore, 3D Medicines, 4basebio, Biohit, Anixa Biosciences and Abingdon Health.

Most iNtRON Biotechnology public comparables operate across Diagnostics & Genomics, Life Sciences Tools, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
HAEMATO0.2x3.1x
Applied BioCode3.8x(12.6x)
Pangaea Oncology4.1x(62.5x)
Osang Healthcare0.9x10.5x
electroCore1.7x1.5x(6.2x)(7.6x)
3D Medicines0.8x(2.2x)
4basebio54.7x(4.7x)
Biohit2.1x2.0x9.7x10.0x

This data is available for Pro users. Sign up to see all iNtRON Biotechnology competitors and their valuation data.

Start Free Trial

iNtRON Biotechnology Investment Activity

iNtRON Biotechnology has invested in 1 company to date.

Latest investment by iNtRON Biotechnology was on December 31st 2020. iNtRON Biotechnology invested in LISCure Biosciences in their $11M Series B round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by iNtRON Biotechnology

LISCure Biosciences
Description
LISCure Biosciences engineers bacteria-mediated immunotherapies for tumors, degenerative neurological disorders, autoimmune conditions, and metabolic diseases from its South Korea base. The company advances seven drug pipelines and two health food pipelines targeting microbiome modulation for therapeutic effects.
HQ CountrySouth Korea
HQ City
Seoul
Deal Date31 Dec 2020
RoundSeries B
Raised$11M
InvestorseBEST; EuBiologics Co., Ltd.; Hana Financial Group; Hana Securities; Hi Investment & Securities; Industrial Bank of Korea; iNtRON Biotechnology; KDB Capital; HLB BioStep; Korea Investment & Securities; LabGenomics
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all iNtRON Biotechnology investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About iNtRON Biotechnology

When was iNtRON Biotechnology founded?iNtRON Biotechnology was founded in 1999.
Where is iNtRON Biotechnology headquartered?iNtRON Biotechnology is headquartered in South Korea.
Is iNtRON Biotechnology publicly listed?Yes, iNtRON Biotechnology is a public company listed on Korea Exchange.
What is the stock symbol of iNtRON Biotechnology?iNtRON Biotechnology trades under 048530 ticker.
When did iNtRON Biotechnology go public?iNtRON Biotechnology went public in 2011.
Who are competitors of iNtRON Biotechnology?iNtRON Biotechnology main competitors include HAEMATO, Applied BioCode, Pangaea Oncology, Osang Healthcare, electroCore, 3D Medicines, 4basebio, Biohit, Anixa Biosciences, Abingdon Health.
What is the current market cap of iNtRON Biotechnology?iNtRON Biotechnology's current market cap is $72M.
What is the current revenue of iNtRON Biotechnology?iNtRON Biotechnology's last fiscal year revenue is $4M.
What is the current EV/Revenue multiple of iNtRON Biotechnology?Current revenue multiple of iNtRON Biotechnology is 11.6x.
Is iNtRON Biotechnology profitable?No, iNtRON Biotechnology is not profitable.
How many companies iNtRON Biotechnology has acquired to date?iNtRON Biotechnology hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies iNtRON Biotechnology has invested to date?As of May 2026, iNtRON Biotechnology has invested in 1 company.
What was the last iNtRON Biotechnology investment?On 31st December 2020 iNtRON Biotechnology invested in LISCure Biosciences, participating in a $11M Series B round, alongside eBEST, EuBiologics Co., Ltd., Hana Financial Group, Hana Securities, Hi Investment & Securities, Industrial Bank of Korea, KDB Capital, HLB BioStep, Korea Investment & Securities, and LabGenomics.
In what companies iNtRON Biotechnology invested in?iNtRON Biotechnology invested in LISCure Biosciences.

See public comps similar to iNtRON Biotechnology

Lists including iNtRON Biotechnology

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial